Experience

Variant Bio

• United States
• Biotechnology Research
• 1 - 100 Employee

• Chief Scientific Officer

  • May 2023 - Present

  Variant partners with communities in underrepresented human populations to study global genetic diversity; data from statistical genetic studies informs the selection of novel therapeutic targets which are being activity pursued to deliver new medicines addressing important unmet medical needs. Variant partners with communities in underrepresented human populations to study global genetic diversity; data from statistical genetic studies informs the selection of novel therapeutic targets which are being activity pursued to deliver new medicines addressing important unmet medical needs.


AvengeBio, Avilar Therapeutics, TVM Life Science Capital, Forkhead Biotherapeutics, Axcella Health
• SAB Member (Avenge, Avilar, Axcella); Director (Forkhead); Senior Advisor (TVM)

  • 2018 - Present


POXEL

• France
• Biotechnology Research
• 1 - 100 Employee

• Chief Scientific Officer

  • Jan 2020 - May 2023

  Clinical stage biopharmaceutical company developing innovative therapeutics for serious chronic metabolic diseases - rare disorders Clinical stage biopharmaceutical company developing innovative therapeutics for serious chronic metabolic diseases - rare disorders



Sigilon Therapeutics, Inc.

• Chief Scientific Officer

  • Jan 2018 - Jan 2020

  Novel engineered cell therapy platform targeting disease areas that include rare genetic enzyme and clotting factor deficiencies, Type 1 diabetes. Novel engineered cell therapy platform targeting disease areas that include rare genetic enzyme and clotting factor deficiencies, Type 1 diabetes.



Eli Lilly and Company

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Vice President Business Development - Emerging Technology and Innovation

  • Aug 2016 - Jan 2018

  Scientific leadership of external innovation opportunities - search and evaluation in areas of breakthrough biology and disruptive technologies across multiple therapeutic areas. Leadership of BD team based in Cambridge MA, Europe, Indianapolis. Execution of partnerships and scientific oversight-input with strategic venture capital partnerships.

• Vice President Endocrine & Cardiovascular Research & Clinical Investigation

  • Dec 2005 - Jul 2016

  Responsible for discovery and clinical drug development for - diabetes, CV-renal, bone-muscle-joint and urology. Oversight of R&D leading to new products including: dulaglutide (Trulicity), tirzepatide (Mounjaro), ultra-rapid insulin (Lyumjev). Lilly China R&D Centre also reported to Moller.



Merck

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Vice President Metabolic Disorders

  • Jul 1995 - Oct 2005

  Leadership of global diabetes and obesity discovery area incuding discovery of sitagliptin (Januvia). Leadership of global diabetes and obesity discovery area incuding discovery of sitagliptin (Januvia).



Harvard Medical School

• United States
• Higher Education
• 700 & Above Employee

• Assistant Professor

  • Jul 1990 - Nov 1995

  Faculty member - research efforts focused on the genetics and molecular pathophysiology of Type 2 diabetes and insulin signaling pathways. Faculty member - research efforts focused on the genetics and molecular pathophysiology of Type 2 diabetes and insulin signaling pathways.